Unique solution enabling researchers to profile human oral drug bioavailability in vitro, in their own laboratories Cambridge, UK, 14 November
CN Bio appoints Lydia Seymour as VP People and Culture to further strengthen leadership team
Key appointment to support continued UK and US team expansion CN Bio, a leading provider of single- and multi-organ microphysiological systems,
CN Bio raises $21 million USD in first close of Series B investment round
Bayland Capital and founding shareholder, CN Innovations Holdings Ltd, to invest $10M and $5.5M, respectively. Investment will expand product
CN Bio selected for NC3R’s SensOoChip Challenge to develop advanced Heart-on-a-Chip
Part of the wider CRACK IT scheme – the multi-challenge competition aims to leverage CN Bio's existing OOC expertise - our MPS development and
CN Bio appoints Joseph Parisi as US Director of Sales
CN Bio appoints Joseph Parisi as US Director of Sales to support accelerated growth in key OOC market CN Bio, a leading Organ-on-a-Chip (OOC)
CN Bio and Altis Biosystems partnership
CN Bio and Altis Biosystems partner to develop next-generation human Gut/Liver in vitro model for advanced ADME studies CN Bio and
PhysioMimix data supports Inipharm’s INI-822 for metabolic liver disease treatment
CN Bio PhysioMimix® Organ-on-a-Chip data supports Inipharm’s INI-822 for metabolic liver disease treatment now in clinical testing. CN Bio, a
OBN Awards 2023 winner!
CN Bio wins ‘Most Impactful Industry Collaboration of the Year’ at the OBN Awards 2023 for ongoing research with the FDA Six-year collaboration
CN Bio appoints Neil Rumbelow as Director of Product Development
Key senior appointment to drive research and development activities for portfolio of PhysioMimix OOC microphysiological systems CN Bio, a